Balanced chromosomal translocations are frequently associated with haematopoietic neoplasms and often involve genes that encode transcription factors, which play critical roles in normal haematopoiesis. Fusion oncoproteins that arise from chimeric genes generated by such translocations are usually stable and consistent molecular markers for a given disease subtype and contribute to the leukaemogenic processes. The t(12;21)(p13;q22) chromosomal translocation is the most frequent illegitimate gene recombination in paediatric cancer, occurring in approximately 25% of common (c) B-cell precursor acute lymphoblastic leukaemia (cALL) cases. The rearrangement results in the in-frame fusion of the 5 0 region of the ETS-related gene, TEL (ETV6), to almost the entire AML1 (RUNX1) locus and is associated with favourable prognosis following conventional therapeutic strategies. We discuss here the prenatal origins of the TEL/AML1 translocation as an initiating mutation, the role of TEL-AML1 in cellular transformation and the molecular mechanisms by which the chimeric protein imposes altered patterns of gene expression.
Introduction
Acute leukaemia is a disease characterized by acquired mutations and clonal expansion of a transformed haematopoietic cell with progeny arrested at some stage of differentiation. Stem cells are considered to be the likely venue for the initial transforming events (Bonnet and Dick, 1997; . In contrast to the epithelial carcinomas, mutations in haematological malignancies frequently involve balanced or reciprocal chromosomal translocations (Rowley, 1998) . These exchanges produce illegitimate recombination of gene loci leading to either deregulated expression of a proto-oncogene or expression of a chimeric fusion gene product with properties different from its wild-type counterparts (Rabbitts, 1994; Look, 1997) . Broadly speaking, the functional consequences of fusion gene formation are activation/ constitutive kinase activation (e.g. BCR-ABL) or the altered transcriptional regulation. Genes that are critical to stem cell development or lineage specification in haematopoiesis are major targets for corruption by gene fusion in leukaemia (Enver and Greaves, 1998) . Genes, such as AML1 (RUNX1), RARa, MLL and TEL (ETV6), have been found rearranged with multiple different partners in distinct types of lymphoid and myeloid leukaemias Rowley, 1998) . These so-called class II mutations (Speck and Gilliland, 2002) result in the expression of chimeric transcription factors, which block differentiation and apoptosis by interfering with the function of their wild-type counterparts. For example, in APL, the PML-RARa chimeric protein blocks differentiation and cell death by interfering with RARa and PML signalling, respectively (He et al., 1999; Rego et al., 2001) . Although required, class II mutations are thought to be insufficient for leukaemogenesis, and recent studies suggest that at the minimum cooperation with growth-promoting tyrosine kinase (TK) mutations (class I), such as FLT3 or RAS, is necessary for the development of a fully malignant disease (Speck and Gilliland, 2002) .
Chromosomal translocations involving either the AML1 or TEL gene constitute some of the most frequently observed genetic aberrations in a variety of different myeloid and lymphoid leukaemias (Rowley, 1998; Greaves, 1999) . The AML1 or RUNX1 gene, which encodes a transcription factor with a DNAbinding domain (DBD) related to Drosophila Runt (and other proteins of the RUNX family), was first identified through its fusion with the ETO gene in t(8;21)(q22;q22)-associated acute myeloid leukaemia (Miyoshi et al., 1991; Erickson et al., 1992; Nisson et al., 1992; Miyoshi et al., 1993) . Subsequently, AML1 was found to be involved in other leukaemogenic translocations, t(16;21), t(12;21) and t(3;21), which involved ETO-related MTG16 (Gamou et al., 1998) , TEL (Golub et al., 1995; Romana et al., 1995a) and EVI1 (Mitani et al., 1994) genes, respectively, and cytogenetic analyses of cells derived from a variety of myeloid malignancies have indicated the possible existence of additional AML1 partner genes (Roulston et al., 1998) . Heritable mutations in the AML1 RUNT DBD were also found to be associated with familial platelet disorder and predisposition to acute myelogenous leukaemia (Osato et al., 1999; Song et al., 1999) . The TEL gene, on the other hand, encodes an ETS family transcription factor identified by its fusion with the PDGFRb locus in cases of chronic myelomonocytic leukaemia with t(5;12)(q33;p13) (Golub et al., 1994) . Subsequently, in a variety of haematopoietic neoplasms, TEL has been found rearranged with a number of different genes (Golub et al., 1996b) , including those encoding other TKs, such as ABL (Papadopoulos et al., 1995) or JAK2 (Lacronique et al., 1997; Peeters et al., 1997) , and the transcription factor AML1 (Romana et al., 1995a; Shurtleff et al., 1995) .
The t(12;21)(p13;q22) chromosomal translocation, which fuses the TEL and AML1 genes is the most common structural chromosomal alteration in paediatric cancer and occurs in approximately 25% of paediatric common or B-cell precursor cell acute lymphoblastic leukaemia (cALL) cases (Romana et al., 1995b; Fears et al., 1996) . It is considerably less prevalent in adult cALL (B3%) and, to date, absent from other subtypes of leukaemia. The leukaemiaassociated TEL-AML1 chimeric protein consists of the TEL sequences situated amino-terminal to the ETS DBD and all known functional regions of AML1 (see Figure 1 for schematic representation), including its RUNT DBD (Golub et al., 1996a; Berger, 1997) . In this respect, TEL-AML1 is structurally distinct from other AML1 fusion proteins, which retain only the aminoterminal RUNT domain and not the C-terminal regulatory sequences of AML1.
An initiating role for TEL-AML1 in pathogenesis of childhood ALL
There is now persuasive evidence that TEL-AML1 usually arises prenatally as an early or initiating mutation. These data derive from studies of identical twins with concordant ALL and retrospective screening of archived neonatal blood spots of children diagnosed with ALL . These analyses required prior identification of genomic breakpoints in TEL and AML1 for individual patient samples by long distance PCR methods (Wiemels and Greaves, 1999) . Breakpoints are scattered throughout the 12 kb intron 5 of TEL and the B100 kb intron 1 on AML1 (Figure 2) . Statistically, there is some degree of microclustering (Wiemels et al., 2000) , but critically, each patient's leukaemic cells have unique, or clonotypic, breakpoints (arrowed in Figure 2a ). The sharing of the same unique clonotypic TEL-AML1 genomic breakpoints and fusion sequences between twins (and that are acquired not constitutive) (see Figure 2b) indicates a single-cell origin. Concordance of disease then arises via spread of clonal progeny from one twin, in which the translocation arises, to the other prenatally via vascular anastomoses within a monochorionic placenta . The identification of clonotypic TEL-AML1 genomic sequences in neonatal blood spots (Wiemels et al., 1999a; Maia et al., 2001; Hjalgrim et al., 2002) provides direct evidence for the existence of the fusion gene at birth. These data are endorsed by the detection of putative preleukaemic B-lineage cells in normal cord blood that harbour TEL/AML1 translocations (Mori et al., 2002 ) (see Figure 3 ). These studies collectively provide a compelling argument for TEL-AML1 arising as a very early event in leukaemogenesis, and although it cannot be proven unequivocally, it may well be the first or initiating event in most cases.
Additional observations from the above studies indicate that although TEL-AML1 may be linked to early preleukaemia clonal expansion, it is insufficient for overt ALL. First, the protracted postnatal interval, or latency, before disease diagnosis can be up to a decade or more (Wiemels et al., 1999b; Maia et al., 2004) and concordance rates in twins are modest at B10% . This suggests that additional or secondary and complementary genetic events are required. Second, the frequency of 'functional' TEL- Figure 1 A schematic representation of the full-length AML1, TEL and TEL-AML1 proteins. The RUNT DBD (RUNT), mSin3A interaction domain (SID, bracket), a region reported to interact with the p300 HAT (p300 ID) and transcriptional activation (activation) in AML1 are as indicated. Carboxy-terminal VWRPY motif that can bind Groucho-related corepressors is also indicated. Different functional regions in the TEL protein such as oligomerisation pointed domain (PD), central repression domain (repression) and ETS DBD are as indicated. Arrows indicate fusion points between TEL and AML1 sequences due to t(12;21). Amino acids that border the key functional domains are numbered with number 1 corresponding to the first methionine
The TEL-AML1 fusion oncoprotein A Zelent et al AML1 fusions in normal newborns is B100 Â the leukaemia rate (Mori et al., 2002) . This interpretation accords with conventional wisdom in two-or multistep models of cancer clone evolution (Knudson, 1992; Vogelstein and Kinzler, 1993) and also fits with results from transgenic modelling with fusion genes (see below). There might not be an exclusive second genetic 'hit', but at diagnosis most cases of ALL with TEL-AML1 fusions have deletion of the nonrearranged or normal TEL allele. Deletions are subclonal to TEL-AML1 fusions (Romana et al., 1996) and are distinct in their genomic boundaries in twins (Maia et al., 2001) , and in relapse versus diagnostic samples from the same individuals . TEL deletions are therefore likely to be postnatal secondary events, albeit a common and integral component of the molecular pathogenesis of cALL . Deletion of normal TEL must have some potent selective advantage in cells carrying TEL-AML1 fusions, which might relate either to a suppressor function of TEL (Fenrick et al., 2000; Rompaey et al., 2000) and/or to the ability of normal TEL protein to dimerize with TEL-AML1 and reduce its transforming activity (McLean et al., 1996; Lopez et al., 1999) . One intriguing proposal, with therapeutic implications, is that fusion genes encoding hybrid transcription factors such as TEL-AML1 also require genetic complementation with mutant or activated kinases (Speck and Gilliland, 2002) . Activated kinases could interfere with the cell cycle and complement the differentiation-blocking activity of chimeric The TEL-AML1 fusion oncoprotein A Zelent et al transcription factors. Whether TEL deletion itself is sufficient to dysregulate the cell cycle in this way remains to be assessed. In acute leukaemias initiated by other gene fusions, including MLL fusions and AML1-ETO, FLT-3 kinase mutations do seem to provide complementary genetic events (Gilliland and Griffin, 2002; Armstrong et al., 2003; Taketani et al., 2004) .
Collectively, these data are compatible with a minimal two-step model for the pathogenesis of childhood ALL and AML, in which chimeric fusion genes provide the first or initiating hit (Figure 4) . Note that for infant ALL with MLL fusions, this evolutionary process must be greatly abbreviated .
Causal mechanisms
Genomic sequence analysis of TEL-AML1 and other fusion genes suggests that the predominant mechanism of chromosome translocation is double-stranded DNA breakage followed by normal but error-prone repair by nonhomologous recombination . However, this begs the question of what causes the initial DNA damage. For MLL gene fusions, there is experimental (Strick et al., 2000) , genetic (Wiemels et al., 1999c; Smith et al., 2002) and epidemiologic (Alexander et al., 2001) evidence that transplacental chemical carcinogenesis may be involved. However, what might be responsible for the relatively high frequency (B1%) of TEL-AML1 fusion generation in normal foetal haematopoiesis? Presumably, nonfunctional fusions (in nonstem cells) occur at an even higher rate. One possibility is that these are 'normal' developmental errors of DNA maintenance reflecting the complexity of embryo and foetal tissue engineering in which cell death, DNA damage and oxidative stress are ubiquitous (Greaves, 1988; . The initiation of other paediatric cancers has similarly been ascribed to developmental accidents (Maris and Denny, 2002) . Even if TEL-AML1 fusion is, in effect, a spontaneous error, the risk of this event occurring may be modified by other factors. There is dietary (Thompson et al., 2001 ) and genetic (Wiemels et al., 2001) evidence that folate has an impact on the risk of infant and childhood leukaemia, and this could well be operative during pregnancy in utero, influencing the likelihood of chromosomal breaks .
Whatever the mechanisms governing chromosomal changes in utero, it is evident that for most cases of childhood leukaemia, the crucial aetiologic bottleneck (Figure 4 ) is the postnatal 'promotional' events or exposures that precipitate the secondary genetic changes, including TEL deletion. Uncovering the nature of these exposures is the objective of major case/control epidemiologic studies in Europe and the US. Although no consensus view has yet emerged, there is now a body of evidence implicating infections in childhood ALL (Greaves, 1997) .
Cell biology and animal models
Understanding the nature of the cellular compartments targeted by leukaemogenic fusion proteins is of fundamental importance both with respect to appreciating the underlying biology of the disease as well as in its treatment (Hope et al., 2003; Grimwade and Enver, 2004 ). An emerging view is that leukaemia represents a dysregulated stem cell-derived clone. Dick and coworkers have provided such a model for AML (Lapidot et al., 1994; Bonnet and Dick, 1997) . In this scenario, rare self-renewing CD34 þ ,CD38À cells retain tumorigenic potential and give rise, through limited differentiation, to the bulk of the leukaemic cells, which display a more mature myeloid phenotype. The CD34 þ CD38À cells may therefore be considered to be both the initial 'target' cells and the 'cancer stem cells' driving and sustaining the disease. Thus they represent the key cellular targets for therapy. While similar considerations clearly apply to CML as a stem cell disease, the case of TEL-AML1-associated cALL is less clear. The overall or 'bulk' phenotype of the leukaemia in children is of an early CD19-positive B-cell progenitor. Attempts to identify the earliest cell, which harbours the TEL/ AML1 translocation, have proved technically difficult due the limited numbers of cells that are available from patients. This caveat aside, attempts so far have only detected the fusion gene in CD19-positive cells with CD34 þ /CD19-cells scoring negative (Hotfilder et al., 2002; Mori et al., 2002) . This would be compatible with TEL-AML1 arising in an early B-lineage committed progenitor/stem cell . However, these data do not necessarily exclude the more primitive CD34-positive stem cell compartment as a cellular target for the initiating translocation.
Experimental modelling of TEL-AML1-associated disease in animals has also provided insight into the cell biology of TEL-AML1-associated cALL. The TEL-AML1 fusion oncoprotein A Zelent et al a requirement for expression in a developmentally more primitive cell compartment and/or the absence of cooperating secondary mutations. In this latter regard, the experiments of Friedman and co-workers are informative (Bernardin et al., 2002) . These workers transduced stem cells with TEL-AML1 containing retroviruses and subsequently transplanted these cells into syngeneic hosts. Transplantation of TEL-AML1-transduced bone marrow cells from a p16/p19-deficient mouse resulted in a high frequency of leukaemia (of unspecified phenotype), which occurred with a relatively short latency. While these results indicate the need for cooperating genetic lesions in TEL-AML1-associated leukaemogenesis, the relevance of this particular combination of mutations in the context of TEL-AML1-associated cALL is unclear. Recently, Tsuzuki et al. (2004) have used a similar experimental approach but focused on identifying the early or preleukaemic effects of TEL-AML1 expression. TEL-AML1 expression was found to inhibit B-cell differentiation leading to an accumulation of early B-cell progenitors and a corresponding deficit in mature B cells. Detailed examination of this partial differentiation arrest reveals effects from the very earliest pro-B cells in the mouse. The size of the haematopoietic stem cell (HSC) compartment was also larger in these animals and furthermore continued to increase with time. This raises the possibility that this very primitive compartment may be responsible for the maintenance and/or expansion of a preleukaemic clone, at least in this model. Despite some increase in myeloid progenitor activity, no block to myeloid differentiation was observed. Overall, this preleukaemic phenotype displays many of the features seen in the common precursor B-cell ALL. Thus, there is (i) a selective differentiation block in the B-cell pathway; (ii) in both cases the block is at an early progenitor cell level (although differences in murine and human B-lymphoid development complicate direct comparison (Ghia et al., 1998) ); and (iii) the differentiation block is incomplete, resulting in the presence of mature B cells in both cases (Mori et al., 2002) . B-cell-specific results have also been reported by Williams and co-workers (Morrow et al., 2004) , who have analysed the effects of enforced expression of TEL-AML1 in foetal liver-derived progenitors. They observed enhanced self-renewal capacity of B-cell progenitors evidenced by increased replating efficiency in colony-forming assays in vitro and an increased repopulating activity on competitive reconstitution assays in vivo. Despite these broad similarities, some detailed aspects of these two murine models (e.g. differentiation block at the B precursor stage) appear different. While this will require further investigation, it seems likely that the use of developmentally distinct stem cell populations in these two studies may be, in some part, accountable for any differences observed. Collectively, however, these studies endorse the view that TEL-AML1 oncoprotein can transform early B-lineage progenitors and initiate a preleukaemia condition. These results parallel the impact of AML1-ETO on early myeloid cell self-renewal and differentiation (Higuchi et al., 2002; Schwieger et al., 2002) . Thus, while expressions of both AML1-ETO and TEL-AML1 within the stem cell compartment appear to inhibit differentiation, the activities of the two molecules appear to be broadly selective for myeloid and Blymphoid lineages, respectively, and are consistent with the lineage selectivity seen in t(8;21)-and t(12;21)-associated leukaemias. The data argue that this striking feature of fusion genes arises not because of a restrictive cell of origin of chromosome translocation itself, but rather as a consequence of cell context-dependent function of the encoded chimeric proteins (Barr, 1998) . It is therefore important to understand how these different chimeric fusions involving AML1-regulated transcription function at the molecular level. One possibility supported by the available molecular evidence (see below) is that TEL-AML1 functions to interfere with normal AML1 activity. While it has been appreciated for some time that AML1 is expressed in most blood cell types including B-lymphocytes, most attention has focused on its role in the specification of HSC, during ontogeny (Okuda et al., 1996; Wang et al., 1996) . Most recently its role in adult haematopoiesis has been addressed using a conditional knockout approach (Ichikawa et al., 2004) . These studies reveal that AML1 function is not required for the maintenance and selfrenewal of HSC, but is required for B-lymphoid differentiation. In addition, loss of AML1 activity results in an increase in multipotent progenitors. These effects are similar to those seen as a result of enforced TEL-AML1 expression (Tsuzuki et al., 2004) , and are therefore consistent with the notion that TEL-AML1 functions as an antagonist of endogenous AML1 activity.
Molecular mechanisms of TEL-AML1 action
Over the past decade results of many studies have highlighted the importance of chromatin-modifying and -remodelling complexes in regulation of gene transcription (Kingston et al., 1996; Kadonaga, 1998) . Through the recruitment of such complexes DNA-binding transacting factors can alter the surrounding nucleosomal structure and either activate or repress transcription from adjacent promoter(s). Whether a given gene is expressed or not (and the level of expression) depends to a large extent on the nature of histone modifications (À the histone code), including methylation and acetylation, which are imposed at its regulatory regions through combinatorial action of transcription factor complexes (Fischle et al., 2003) . Consistent with early findings that histone hyper-and hypoacetylation is linked to transcriptionally active and silent chromatin, respectively (Vidali et al., 1978) , many transcriptional activators and repressors, including leukaemia-associated fusion oncoproteins, have been shown to recruit cofactors with intrinsic and/or associated histone acetyltransferases (HATs, coactivators) and deacetylases (HDACs, corepressors) (Grunstein, 1997; Hassig and Schreiber, 1998) . AML1 has been shown to function
The TEL-AML1 fusion oncoprotein A Zelent et al as a DNA-binding transcriptional activator required for the expression of genes whose products are associated with blood cell development, such as TCRd (HernandezMunain and Krangel, 1994) , interleukin-3 (Uchida et al., 1997) and PU.1 transcription factor (Okada et al., 1998) . Activation of gene expression by AML1 and its positive role in myeloid cell differentiation has been correlated with its ability to interact with the p300 HAT (Kitabayashi et al., 1998) .
A number of previous studies have also suggested that, in a specific promoter and/or cell context, AML1 can function as a transcriptional repressor (Takahashi et al., 1995) . The carboxy-terminal VWRPY motif of AML1 can interact (Aronson et al., 1997; Levanon et al., 1998) with Groucho-related corepressors, TLE1-4 (Fisher and Caudy, 1998; Imai et al., 1998) . The mechanism of transcriptional repression by the Groucho family of proteins may also, at least in part, be mediated through HDACs (Chen et al., 1999) . AML1 can also interact with mSin3A corepressor and HDACs (Fenrick et al., 1999; Guidez et al., 1999; Lutterbach et al., 2000; Petrie et al., 2003) . Since the VWRPY motif is not required for this interaction, it is likely that in addition to repression through the Groucho related proteins, AML1 may also repress transcription through recruitment of mSin3A/ HDAC complexes. The particular mode of repression, or AML1 action in general, could be specific to different target genes and be subject to regulation through posttranslational protein modification and/or interaction with other factors (see Figure 5a) . Consistent with the above, association mSin3A with AML1 is regulated by phosphorylation (Imai et al., 2004) . When AML1 is phosphorylated on specific serine residues by extracellular signal-regulated kinases, which positively regulate its transcriptional activity, it dissociates from mSin3A and no longer colocalizes with the corepressor in nuclear matrix. These results could suggest that target genes for AML1 repressor are distinct from those that are activated by AML1. However, one cannot exclude that translocation from nuclear matrix may involve DNAbound AML1/promoter complex.
In contrast to AML1, transiently expressed TEL-AML1 fusion proteins generally repress the activities of reporter constructs driven by regulatory regions derived from haematopoietic-specific genes and/or antagonize their AML1-dependent activation Fears et al., 1997) . Work from a number of laboratories has shown that the transcriptional activities of TEL- Figure 5 A hypothetical model for the molecular mechanism of TEL-AML1 action. (a) AML1 is a factor whose transcription activating and repressing abilities depend on recruitment of p300 and mSin3A/HDAC, respectively, and are regulated by some, as yet, poorly defined processes (phosphorylation, for example). Binding of AML1 to its target genes is shown to occur in association with its regulatory subunit CBFb. When associated with mSin3A, AML1 represses transcription through indirect recruitment of HDAC which removes the acetyl groups (Ac) from lysine residues located in amino-terminal tails of histones (H3 and H4), thus allowing for the formation of compact or repressed chromatin and markedly reducing accessibility of a given promoter to basal transcriptional machinery. Given an appropriate stimulus, the above process is reversed as AML1 dissociates from mSin3A/HDAC and associates with p300 HAT. Association of AML1 with either mSin3A or p300 may also dependent on the context of the regulatory region of a given AML1 target gene. This model does not exclude the possibility that AML1 can repress transcription through other corepressors, such as Groucho/TLE, which for simplicity are not indicated. (b) In the case of TEL-AML1, the abilities of TEL moiety to dimerize and to bind N-CoR and mSin3A corepressors allow for the formation of a very stable repressor complex and renders the chimeric protein, which includes the DNA-binding Runt domain of AML1, resistant to the regulation depicted in (a). Therefore, the TEL-AML1 fusion protein that retains the ability to bind the AML1 target sequences has a potential to function as a constitutive HDACdependent repressor causing deregulation of AML1 target genes. Although p300 may be still capable of association with the AML1 moiety of the TEL-AML1, its HAT activity would likely not function correctly in the context of the fusion protein. Owing to the TEL dimerization/oligomerization PD, the TEL-AML1 fusion protein binds to the AML1 target sequences as a homodimer or an oligomer (not shown). The functional requirements of CBFb for DNA binding of TEL-AML1 dimers or oligomers to AML1 binding sites are not clear (?)
The TEL-AML1 fusion oncoprotein A Zelent et al AML1 involve recruitment of nuclear receptor corepressor/HDAC complexes to the TEL moiety of the fusion protein (Chakrabarti and Nucifora, 1999; Fenrick et al., 1999; Guidez et al., 2000) . Similar findings have been reported for other AML1 fusion proteins (see other articles in this issue). Consistent with such results, TEL-AML1-mediated repression can be relieved by HDAC inhibitors such as trichostatin A (Fenrick et al., 1999; Guidez et al., 1999) .
Given that AML1 may function as a regulated transcription factor, the fusion of its DBD with TEL sequences would convert it to an HDACdependent constitutive repressor and contribute to leukaemogenesis via imposition of an altered pattern of AML1 target gene expression (see model in Figure 5 ). In order to bind effectively to its DNA target sites, AML1 needs to dimerize with a non-DNA-binding regulatory protein CBFb (Meyers et al., 1993; Ogawa et al., 1993; Wang et al., 1993) , which is itself encoded by a gene disrupted by a recurrent chromosomal rearrangement, inv(16), in acute myeloid leukaemia (Liu et al., 1993) . It remains to be shown whether in the context of the TEL-AML1 (or other AML1 fusions) CBFb is required for the stability of RUNT domain and efficient DNA binding. The wild-type TEL, on the other hand, can self-associate via its PD domain and is thought to form dimers or oligomers (Jousset et al., 1997; Lopez et al., 1999; Mavrothalassitis and Ghysdael, 2000) . PD of TEL appears to be required for repression, however, it is unclear whether this region acts as a repressor domain or whether dimerization/oligomerization of TEL is required for affective association of corepressors and transcriptional repression of target sequences. PD can interact with mSin3A and a central repression domain, located between PD and ETS DBD, has been shown to interact with N-CoR and HDACs (Fenrick et al., 1999; Guidez et al., 2000; Wang and Hiebert, 2001; Petrie et al., 2003) . It is likely that oligomerization of TEL allows for stable formation of repressor-corepressor complexes as replacement of TEL PD with a heterologous dimerization/oligomerization domain restores its ability to repress transcription from a cotransfected reporter constructs (Mavrothalassitis and Ghysdael, 2000) . In this respect, it is worth noting that recent results have also indicated that the mechanism of inv(16) generated CBFb-SMMHC fusion oncoprotein action may be to stabilise the association of the corepressor complex with the AML1 protein .
In addition to corepressor/HDAC recruitment acquisition of TEL sequences by AML1 moiety of the fusion protein (see Figure 5 ) may have additional functional consequences. For example, dimerization or oligomerization of AML1 RUNT DBD via the amino-terminal TEL could allow for higher affinity binding to multiple AML1 DNA-binding sites than for monomeric RUNT domain, thus antagonizing action of the wild-type AML1. Higher affinity for multiple AML1 binding sites has been demonstrated for AML1-ETO (Bushweller et al., 2003) . This property is thought to account for the observed dominant-negative effects of AML1-ETO on function of AML1 in haematopoietic development (Yergeau et al., 1997; Okuda et al., 1998) .
Therapeutic implications
Important therapeutic implications of these functional insights are that agents capable of inhibiting enzymatic components of the corepressor complexes could potentially revert the differentiation blocks imposed by TEL-AML1 and other fusion gene encoded oncoproteins. Although ALL with TEL-AML1 is usually a low-risk disease, it too could benefit from novel, less toxic therapies targeting activity of the chimeric protein, particularly in low proportion of more difficult and/or relapsed cases. Addition of HDAC inhibitors and/or other agents that relief transcriptional repression (DNA demethylating agent 5-azacytidine, for example) with current therapies may allow for dose reduction and hence lower therapeutic toxicities of currently used drugs. This view is consistent with results indicating that treatment intensity may affect outcome of the patients with cALL (Takahashi et al., 1998) . Such combinatorial therapies may also more effectively target the premalignant clone, thus reducing the likelihood of a relapsed disease. In this context, there is evidence based on TEL deletion analysis and IGG clonotypic sequences (Konrad et al., 2003) that 'late' relapses, that is, off treatment, in this leukaemia may derive from a persistent, therapy-resistant TEL-AML1 preleukaemic clone. Late relapses of TEL-AML1-positive ALL are very rare in the Dana Farber chemotherapy protocol that includes high-dose L-asparaginase as part of the intensification regime (McLean et al., 1996) . Correspondingly, ALL blast cells with TEL-AML1 are known to be selectively sensitive in vitro to this drug (Ramakers-van Woerden et al., 2000) .
